@article {1589998,
	title = {KRAS G12C inhibition and innate immune targeting},
	journal = {Expert Opin Ther Targets},
	year = {2021},
	month = {2021 Mar 28},
	pages = {1-8},
	abstract = {INTRODUCTION:  mutations drive tumorigenesis by altering cell signaling and the tumor immune microenvironment. Recent studies have shown promise for KRAS-G12C covalent inhibitors, which are advancing rapidly through clinical trials. The sequencing and combination of these agents with other therapies including immune checkpoint blockade (ICB) will benefit from strategies that also address the immune microenvironment to improve durability of response.

AREAS COVERED: This paper reviews KRAS signaling and discusses downstream effects on cytokine production and the tumor immune microenvironment. RAS targeted therapy is introduced and perspectives on therapeutic targeting of KRAS-G12C and its immunosuppressive tumor microenvironment are offered.

EXPERT OPINION: The availability of KRAS-G12C covalent inhibitors raises hopes for targeting this pervasive oncogene and designing better therapeutic combinations to promote anti-tumor immunity. A comprehensive mechanistic understanding of KRAS immunosuppression is required in order to prioritize agents for clinical trials.},
	issn = {1744-7631},
	doi = {10.1080/14728222.2021.1902991},
	author = {Tani, Tetsuo and Kitajima, Shunsuke and Conway, Ella B and Knelson, Erik H and Barbie, David A}
}
